Раздел 1.3.1. Ferrer-Santacreu E.M. et al., Enchondroma versus Low-Grade Chondrosarcoma in Appendicular Skeleton: Clinical and Radiological CriteriaJ Oncol. 2012:2012:437958.
2. Crim J., Schmidt R., Layfield L., Hanrahan C., Manaster B.J. Can imaging criteria distinguish enchondroma from grade 1 chondrosarcoma? Eur J Radiol. 2015 Nov;84(11):2222-30.
3. Geirnaerdt M.J., Hermans J., Bloem J.L., Kroon H.M., Pope T.L., Taminiau A.H., Hogendoorn P.C. Usefulness of radiography in differentiating enchondroma from central grade 1 chondrosarcoma AJR Am J Roentgenol. 1997 Oct;169(4):1097-104.
4. Murphey M.D., Walker E.A., Wilson A.J., Kransdorf M.J., Temple H.T., Gannon F.H. From the archives of the AFIP: imaging of primary chondrosarcoma: radiologic-pathologic correlation. Radiographics. 2003 Sep-Oct;23(5):1245-78.
5. Amary M.F., Damato S., Halai D., Eskandarpour M., Berosha F., Bonar F., McCarthy S.M., Fantin V.R., Straley K.S., Lobo S., Aston W., Campbell P., Presneau N., Flanagan A.M. Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2. Nat Genet. 2011 Nov 6;43(12):1262-5.
6. Mirra J.M., Gold R., Eckardt J.J. A new histologic approach to the differentiation of enchondroma and chondrosarcoma of the bones. A clinicopathologic analysis of 51 cases Clin Orthop Relat Res. 1985 Dec:(201):214-37.
7. Giuffrida A.Y., Burgueno J.E., Koniaris L.G., Gutierrez J.C., Duncan R., Scully S.P.
Chondrosarcoma in the United States (1973 to 2003): an analysis of 2890 cases from the SEER database. J Bone Joint Surg Am. 2009 May;91(5):1063-72.
8. Булычева И.В., Федорова А.В., Klein M.J., Соловьев Ю.Н. Атлас ортопедической патологии. Том 1. Хрящеобразующие опухоли. Монография. АБВ-пресс, 2021. Твердый переплет, 192 с., илл. ISBN 978-5-6044613-8-9.
9. Ahmed A.R., Tan T-S., Unni K.K., Collins M.S., Wenger D.E., Sim F.H. Secondary chondrosarcoma in osteochondroma: report of 107 patients. Clin Orthop Relat Res. 2003 Jun:(411):193-206.
10. De Andrea C. E., Wiweger M.I., Bovee J.V.M., Romeo S., Hogendoorn P.C.W. Peripheral chondrosarcoma progression is associated with increased type X collagen and vascularization. Virchows Arch. 2012 Jan;460(1):95-102.
11. Bwernard S.A., Murphey M.D., Flemming D.J., Kransdoef M.J. Improved differentiation of benign osteochondromas from secondary chondrosarcomas with standardized measurement of cartilage cap at CT and MR imaging. Radiology. 2010 Jun;255(3):857-65.
12. Bjornsson J., McLeod R.A., Unni K.K., Ilstrup D.M., Pritchards D.J. Primary chondrosarcoma of long bones and limb girdles. Cancer. 1998 Nov 15;83(10):2105-19.
13. Evans H.L., Ayala A.G., Romsdahl M.M. Prognostic factors in chondrosarcoma of bone: a clinicopathologic analysis with emphasis on histologic grading
Cancer. 1977 Aug;40(2):818-31.
14. Fromm J., Klein A., Baur-Melnyk A., Knosel T., Lindner L., Birkenmaier C., Roeder F., Jansson V., Durr H.R. Survival and prognostic factors in conventional central chondrosarcoma.BMC Cancer. 2018 Aug 24;18(1):849.
15. Angelini A., Guerra G., Mavrogenis A.F., Pala E., Picci P., Ruggieri P. Clinical outcome of central conventional chondrosarcoma.J Surg Oncol. 2012 Dec;106(8):929-37.
16. Gelderblom H., Hogendoorn C.W.,Dijkstra S.D., van Rijswijk C.S.,Krol A.D., Taminiau A.H.M., Bovee J.V.M.G. The clinical approach towards chondrosarcoma. Oncologist. 2008 Mar;13(3):320-9.
17. Amary M.F., Bacsi K., Mggiani F., Damato S., Halai D., Berisha F., Pollock R., O’DonnellP., Grigoriadis A., Diss T., Eskandarpour M., Presneau N., Hogendoorn P.C.W.,Futreal A., Tirabosco R., Flanagan A.M. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours.J Pathol. 2011 Jul;224(3):334-43.
18. MirraJ.M., Gold R., Downs J., Ekcardt J.J. A new histologic approach to the differentiation of enchondroma and chondrosarcoma of the bones. A clinicopathologic analysis of 51 cases.Clin Orthop Relat Res. 1985 Dec:(201):214-37.
19. Douis H., Singh L., Saiffuddin A. MRI differentiation of low-grade from high-grade appendicular chondrosarcoma. Eur Radiol. 2014 Jan;24(1):232-40.
20. Федорова А.В. Современные возможности лучевой диагностики хрящеобразующих опухолей скелета. Канд. дисс., 2019.
21. Porter D.E., Ngoh C., Fei L., Chondrosarcoma transformation in hereditary multiple exostoses: A systematic review and clinical and cost-effectiveness of a proposed screening modelJ Bone Oncol. 2018 Oct 4:13:114-122.
22. Sim F.H.,Wenger D.E., Collins M.S., Unni K.K.., Tan T-S.T., Ahmed A.R., Secondary chondrosarcoma in osteochondroma: report of 107 patients Clin Orthop Relat Res. 2003 Jun:(411):193-206.
23. Bovee J.V., Cleton-Jansen., Kuipers-Dijkshoorn N.J., van den Broek L.J., Tminiau A.H., Coenelisse C.J., Hogendoorn P.C. Loss of heterozygosity and DNA ploidy point to a diverging genetic mechanism in the origin of peripheral and central chondrosarcoma. Genes Chromosomes Cancer. 1999 Nov;26(3):237-46.
24. Fritchie K., Folpe A.L., Shon W., ERG expression in chondrogenic bone and soft tissue tumours. J Clin Pathol. 2015 Feb;68(2):125-9.
25. Bauer T.W., Dorfman H.D., Latham J.T. Periosteal chondroma. A clinicopathologic study of 23 cases Am J Surg Pathol 1982 Oct;6(7):631-7.
26. Brien E.W., Mirra J.M., Luck J.V. Benign and malignant cartilage tumors of bone and joint: their anatomic and theoretical basis with an emphasis on radiology, pathology and clinical biology. II. Juxtacortical cartilage tumors Skeletal Radi. 1999 Jan;28(1):1-20.
27. Lewis M.M., Kenan S.,Yabut S.M., Norman A.,Steiner G. Periosteal chondroma. A report of ten cases and review of the literature, Clin Orthop Relat Res. 1990 Jul:(256):185-92.
28. Dahlen A., Mertens F., Rydholm A., Brosjo O.,Wejde J.,Mandahl N.,Panagopoulos I Fusion, disruption, and expression of HMGA2 in bone and soft tissue chondromas. Mod Pathol. 2003 Nov;16(11):1132-40.
29. Damato S., Aloriani M., Bonar F., McCarthy, S.W., Cannon S.R.,O’Donnel R., Tirabosco R., Amaray M.F., Flanagan A.M. Periosteal chondrosarcoma: a histopathological and molecular analysis of a rare chondrosarcoma subtype.Histopathology. 2012 Jan;60(2):363-5.
30. Present D., Bacchini P., Pignatti G., Picci P., Bertoni F., Campanacci M. Clear cell chondrosarcoma of bone. A report of 8 cases.Skeletal Radiol. 1991;20(3):187-91.
31. Bjornsson J., Unni K.K., Dahlin D.C., Beabout J.W., Sim F.H. Clear cell chondrosarcoma of bone. Observations in 47 cases.Am J Surg Pathol. 1984 Mar;8(3):223-30.
32. Itala A., Leerapun T., Inwards C., Collins M., Scully S.P. An institutional review of clear cell chondrosarcoma.Clin Orthop Relat Res. 2005 Nov:440:209-12.
33. Kalil R.K., Inwards C.Y., UnniK.K., Bertoni F., Bacchini P., Wenger D.E., Sim F.H. Dedifferentiated clear cell chondrosarcoma.Am J Surg Pathol. 2000 Aug;24(8):1079-86.
34. Vencio E.F., Reeve C.M., Unni K.K., Nascimento A.G. Mesenchymal chondrosarcoma of the jaw bones: clinicopathologic study of 19 cases.Cancer. 1998 Jun 15;82(12):2350-5.
35. Cesari M., Bertoni F., Bacchini P., Mercuri M., Palmerini E., Ferrari S. Mesenchymal chondrosarcoma. An analysis of patients treated at a single institution. Tumori. 2007 Sep-Oct;93(5):423-7.
36. Fanburg-Smith J.C., Auerbach A., Marwaha J.S., Wang Z., Santi M., Judkins A., Rushing E.J. Immunoprofile of mesenchymal chondrosarcoma: aberrant desmin and EMA expression, retention of INI1, and negative estrogen receptor in 22 female-predominant central nervous system and musculoskeletal cases .Ann Diagn Pathol. 2010 Feb;14(1):8-14.
37. Xu J., Li Dasen.,Xie L., Tang S., Guo W. Mesenchymal chondrosarcoma of bone and soft tissue: a systematic review of 107 patients in the past 20 years. PLoS One. 2015 Apr 7;10(4)
38. Meijer D., de Jong D., Pansuriya T.C., van den Akker B., Picci P., Szuhai K., Bovee J.V.G.M. Genetic characterization of mesenchymal, clear cell, and dedifferentiated chondrosarcoma.Genes Chromosomes Cancer. 2012 Oct;51(10):899-909.
39. Tsuda Y., Ogura K., Hakozaki M., Kikuta K., Ae K., Tsuchiya H., Iwata S., Ueda T., Kawano H., Kawai A. Mesenchymal chondrosarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study on 57 patients.J Surg Oncol. 2017 May;115(6):760-767.
40. Staals E., Bacchini P., Mercuri M., Bertoni F. Dedifferentiated chondrosarcomas arising in preexisting osteochondromas J. Bone Joint Surg. Am 2007 May;89(5):987-93.
Franco Bertoni.
41. Grimer R.J., Gosheger G., Taminiau A., Biau D., Matejovsky Z., Kollender Y., San-Julian M., Gherlinzoni F., Ferrari C. Dedifferentiated chondrosarcoma: prognostic factors and outcome from a European group.Eur J Cancer. 2007 Sep;43(14):2060-5.
42. Bridge J.A., DeBoer J., Travis J., Johansson S.L., Elmberger G., Noel S.M., Neff J.R. Simultaneous interphase cytogenetic analysis and fluorescence immuniphenotyping of dedifferentiated chondrosarcoma. Implications for histopathogenesis // Am. J. Pathol. 1994. Vol.144. Р. 215-220.
43. Dickey I.D., Rose P.S., Fuchs B. et al. Dedifferentiated chondrosarcoma; the role of chemotherapy with updated outcomes // J. Bone Joint Surg. 2004. 86AQ. P. 2412-2418.
44. Falcone G., Rossi E.D., Maccauro G., de Santis V., Rosa M.A., Capelli A., Fadda G. Diagnostic relevance of the immunohistochemical detection of growth factors in benign and malignant cartilaginous tumors // Appl. Immunohistochem Mol. Morphol.-2006.-Vol.14.-p.334-340.
45. Staals E.L., Bacchini P., Mercuri M., Bertoni F. Dedifferentiated chondrosarcomas arising in preexisting osteochondromas // J. Bone Joint Surg. Am. 2007. Vol. 89.
46. Wold L. Dedifferentiated chondrosarcoma // 10
th Mayo Clinic International Surgical Pathology Symposium, Dublin. 2003.
47. Rozeman L.B., Briare de Bruijn H.B., Bacchini P., Staals E.L., Bertoni F., Bovee J.M.G., Hogendoorn P.C.W. Dedifferentiated peripheral chondrosarcomas: regulation of EXT-downstream molecules and differentiation-related genes. Mod Pathol. 2009 Nov;22(11):1489-98.
48. Fetsch J.F., Vinh T.N., Remotti F., Walker E.A., Murphey M.D., Sweet D.E. Tenosynovial (extraarticular) chondromatosis: an analysis of 37 cases of an underrecognized clinicopathologic entity with a strong predilection for the hands and feet and a high local recurrence rate. Am J Surg Pathol. 2003 Sep;27(9):1260-8.
49. Murphey M.D., Vidal J.A., Fanburg-Smith J.C., Gajewski D.A. Imaging of synovial chondromatosis with radiologic-pathologic correlation. Radiographics. 2007 Sep-Oct;27(5):1465-88.
50. Walker E.A., Murphey M.D., Fetsch J.F. Imaging characteristics of tenosynovial and bursal chondromatosis. Skeletal Radiol. 2011 Mar;40(3):317-25.
51. Baumhoer D., Amaray F., Flanagan A.M. An update of molecular pathology of bone tumors. Lessons learned from investigating samples by next generation sequencing. Genes Chromosomes Cancer. 2019 Feb;58(2):88-99.
52. Wittkop B., Davies A.M., Mangham D.C. Primary synovial chondromatosis and synovial chondrosarcoma: a pictorial review. Eur Radiol. 2002 Aug;12(8):2112-9.
53. Evans S., Boffano M., Chaudhry S., Jeys L., Grimer R. Synovial chondrosarcoma arising in synovial chondromatosis. Sarcoma. 2014:2014:647939.
54. 1. Fetsch J.F., Vinh T.N., Remotti F., Walker E.A., Murphey M.D., Sweet D.E. Tenosynovial (extraarticular) chondromatosis: an analysis of 37 cases of an underrecognized clinicopathologic entity with a strong predilection for the hands and feet and a high local recurrence rate. Am J Surg Pathol. 2003 Sep;27(9):1260-8.
55. Murphey M.D., Vidal J.A., Fanburg-Smith J.C., Gajewski D.A. Imaging of synovial chondromatosis with radiologic-pathologic correlation. Radiographics. 2007 Sep-Oct;27(5):1465-88.
56. Walker E.A., Murphey M.D., Fetsch J.F. Imaging characteristics of tenosynovial and bursal chondromatosis. Skeletal Radiol. 2011 Mar;40(3):317-25.
57. Baumhoer D., Amaray F., Flanagan A.M. An update of molecular pathology of bone tumors. Lessons learned from investigating samples by next generation sequencing. Genes Chromosomes Cancer. 2019 Feb;58(2):88-99.
58. Wittkop B., Davies A.M., Mangham D.C. Primary synovial chondromatosis and synovial chondrosarcoma: a pictorial review. Eur Radiol. 2002 Aug;12(8):2112-9.
59. Evans S., Boffano M., Chaudhry S., Jeys L., Grimer R. Synovial chondrosarcoma arising in synovial chondromatosis. Sarcoma. 2014:2014:647939.
60. Schwab J.H., Antonescu C.R., Athanasian E.A., Boland P.J., Healey J.H.,Morris C.D. A comparison of intramedullary and juxtacortical low-grade osteogenic sarcoma. Clin Orthop Relat Res. 2008 Jun;466(6):1318-22.
61. Demicco E.G., Deshpande V., Nielsen G.P., Kattapyram S.V., Rosenberg A.E. Well-differentiated osteosarcoma of the jaw bones: a clinicopathologic study of 15 cases. Am J Surg Pathol. 2010 Nov;34(11):1647-55.
62. Malhas A.M., Sumathi V.P., Menna C.,m Carter S.R., Tillman R.M., Jeys L., Grimer R.J. Low-grade central osteosarcoma: a difficult condition to diagnose. Sarcoma. 2012:2012:764796.
63. Andersen K.A., Sundaram M., Unni K.K.,Sim F.H. Imaging features of low-grade central osteosarcoma of the long bones and pelvisTop of Form. Skeletal Radiol. 2004 Jul;33(7):373-9.
64. Kurt A.M., Unni K.K., McLeod R.A., Pritchard D.J. Low-grade intraosseous osteosarcoma. Cancer. 1990 Mar 15;65(6):1418-28.
65. Mirabello L., Savage S.A. Using epidemiology and genomics to understand osteosarcoma etiology.Sarcoma. 2011:2011:548151.
66. Baumhoer D., Brunner P., Eppenberger-Castori S., Smida J., Nathrath M., Jundt G. Osteosarcomas of the jaws differ from their peripheral counterparts and require a distinct treatment approach. Experiences from the DOESAK Registry. Oral Oncology. 2014 Feb;50(2):147-53.
67. Bacci G., Fabbri N., Balladelli A., Foeni C., Palmerini E., Picci P. Treatment and prognosis for synchronous multifocal osteosarcoma in 42 patientsJ Bone Joint Surg Br. 2006 Aug;88(8):1071-5.
68. Angelini A., Mayrogenis A.F., Trovarelli G., Ferrari S., Picci P., Ruggieri P. Telangiectatic osteosarcoma: a review of 87 cases.J Cancer Res Clin Oncol. 2016 Oct;142(10):2197-207.
69. Wallace S., Edeiken J., Jimenez J., Link M., Carrasco H., Chawla S., Jaffe N., Raymond A.K., Ro J.Y., Ayala A.G. Small cell osteosarcoma. A clinicopathologic study of 27 cases.Cancer. 1989 Nov 15;64(10):2162-73.
70. McLeod R.A., Pritchard D.J., Unni K.K., Mervak T.R. Telangiectatic osteosarcoma.Clin Orthop Relat Res. 1991 Sep:(270):135-9.
71. Geirnaerdt M.J., Bloem J.L., van der Woude H.J., Taminiau A.H., Noov M.A., Hogendoorn P.C. Chondroblastic osteosarcoma: characterisation by gadolinium-enhanced MR imaging correlated with histopathology.Skeletal Radiol. 1998 Mar;27(3):145-53.
72. Hickson I.D., Chu W.K. RecQ helicases: multifunctional genome caretakers. Nat Rev Cancer. 2009 Sep;9(9):644-54.
73. Squire J.A., Pei Jianming., Marrano P., Beheshti B., Bayani J., Lim G., Moldovan L., Zeilenska M. High-resolution mapping of amplifications and deletions in pediatric osteosarcoma by use of CGH analysis of cDNA microarrays.Genes Chromosomes Cancer. 2003 Nov;38(3):215-25.
74. Matsuno T., Unni R.R., Dahlin D.C. Telangiectatic osteogenic sarcoma. Cancer. 1976 Dec;38(6):2538-47.
75. Hauben E.I., Weeden S., Pringle J., van Marck E.F., Hogendoorn P.C.W. Does the histological subtype of high-grade central osteosarcoma influence the response to treatment with chemotherapy and does it affect overall survival? A study on 570 patients of two consecutive trials of the European Osteosarcoma Intergroup.Eur J Cancer. 2002 Jun;38(9):1218-25.
76. Machado I., Navarro S., Picci P., Lombart-Bosch A. The utility of SATB2 immunohistochemical expression in distinguishing between osteosarcomas and their malignant bone tumor mimickers, such as Ewing sarcomas and chondrosarcomas. Pathol Res Pract. 2016 Sep;212(9):811-6.
77. Nakajima H., Sim F.H.,Bond J.R., Unni K.K. Small cell osteosarcoma of bone. Review of 72 cases. Cancer. 1997 Jun 1;79(11):2095-106.
78. Cates J.M.M. Modeling Continuous Prognostic Factors in Survival Analysis: Implications for Tumor Staging and Assessing Chemotherapy Effect in Osteosarcoma. Am J Surg Pathol.2018 Apr;42(4):485-491.
79. Блудов А.Б. Роль методов лучевой диагностики в оценки эффективности предоперационной химиотерапии у больных с саркомами костей. Канд. дисс., 2013.
80. Okada K., Frassica., Sim F.H., Beabout J.W., Bond J.R., Unni K.K. Parosteal osteosarcoma. A clinicopathological study.J Bone Joint Surg Am. 1994 Mar;76(3):366-78.
81. Chen G., Xu Qiang., Zhang B., Dai M. Parosteal osteosarcoma of the fibula in a middle-aged patient: A case report. Medicine (Baltimore). 2019 Jan;98(2).
82. Gisselson D., Palsson E., Hoglung M., Domanski H., Merytens F., Pandis N., Sciot R., Dal Cin P., Bridge J.A., Mandahl N. Differentially amplified chromosome 12 sequences in low-and high-grade osteosarcoma.Genes Chromosomes Cancer. 2002 Feb;33(2):133-40.
83. Reith J.D., Donahue F.I., Hornicek F.J. Dedifferentiated parosteal osteosarcoma with rhabdomyosarcomatous differentiation.Skeletal Radiol. 1999 Sep;28(9):527-31.
84. Wold L.E., Unni K.K., Beabout J.W., Sim F.H., Dahlin D.C. Dedifferentiated parosteal osteosarcoma.J Bone Joint Surg Am. 1984 Jan;66(1):53-9.
85. Cesari M., Alberghini M., Vanel D., Palmerini E., Staals E.L., Longhi A., Abate M., Ferrari C., Balladelli A., Ferrari S. Periosteal osteosarcoma: a single-institution experience.Cancer. 2011 Apr 15;117(8):1731-5.
86. Chan C.M., Lindsay A.D., Spiguel A.R.V., Gibbs Jr C.P., Scarborough M. Periosteal Osteosarcoma: A Single-Institutional Study of Factors Related to Oncologic Outcomes.Sarcoma. 2018 Sep 27:2018:8631237.
87. Murphey M.D., Jelinek J.S., Temple H.T., Flemming D.J., Gannon F.H. Imaging of periosteal osteosarcoma: radiologic-pathologic comparison.Radiology. 2004 Oct;233(1):129-38.
88. Bertoni F., Boriani S., Laus M., Campanacci M. Periosteal chondrosarcoma and periosteal osteosarcoma. Two distinct entities.J Bone Joint Surg Br. 1982;64(3):370-6.
89. Gulia A., Puri A., Pruth M., Desai S. Oncological and functional outcome of periosteal osteosarcoma.Indian J Orthop. 2014 May;48(3):279-84.
90. Unni K.K., Dahlin D.C., Beabout J.W. Periosteal osteogenic sarcomf.Cancer. 1976 May;37(5):2476-85.
91. Machado I., Navarro S., Picci P., Llombart-Bosch A. The utility of SATB2 immunohistochemical expression in distinguishing between osteosarcomas and their malignant bone tumor mimickers, such as Ewing sarcomas and chondrosarcomas. Pathol Res Pract. 2016 Sep;212(9):811-6.
92. Okada K., Unni K.K., Swee R.G., Sim F.H. High grade surface osteosarcoma: a clinicopathologic study of 46 cases.Cancer. 1999 Mar 1;85(5):1044-54.
93. Vanel D., Picci P., De Paolis M., Mercuri M. Radiological study of 12 high-grade surface osteosarcomas.Skeletal Radiol. 2001 Dec;30(12):667-71.
94. Staals E.L., Bacchini P., Bertoni F. High-grade surface osteosarcoma: a review of 25 cases from the Rizzoli Institute.Cancer. 2008 Apr 1;112(7):1592-9.
95. Lopez C., Thomas D.V., Davies A.M. Neoplastic transformation and tumour-like lesions in Paget's disease of bone: a pictorial review.Eur Radiol. 2003 Dec:13 Suppl.4:L151-63.
96. Vuillemin-Bodagh V., Parlier-Cuau C., Cywiner-Golenzer^ Quillard A., Kaplan G., Laredo J.D. Multifocal osteogenic sarcoma in Paget's disease.Skeletal Radiol. 2000 Jun;29(6):349-53.
97. Smith J., Botet J.F., Yeh S.D. Bone sarcomas in Paget disease: a study of 85 patients. Radiology,1984 Sep;152(3):583-90. 98. Sheppard D.G., Libshitz H.I. Post-radiation sarcomas: a review of the clinical and imaging features in 63 cases.Clin Radiol. 2001 Jan;56(1):22-9.
99. Inoue Y.Z., Frassica F.J., Sim F.H., Unni K.K., Petersen I.A., McLeod R.A. Clinicopathologic features and treatment of postirradiation sarcoma of bone and soft tissue. J Surg Oncol. 2000 Sep;75(1):42-50.
100. McMaster M.L., Goldstein A.M., Bromley C.M., Ishibe N., Parry D.M. Chordoma: incidence and survival patterns in the United States, 1973-1995.Cancer Causes Control. 2001 Jan;12(1):1-11.
101. Lauer S.R., Edgar M.A., Gardner J.M., Sebastian A., Weiss S.W. Soft tissue chordomas: a clinicopathologic analysis of 11 cases.Am J Surg Pathol. 2013 May;37(5):719-26.
102. Park S-A.,Kim H.S. F-18 FDG PET/CT evaluation of sacrococcygeal chordoma.Clin Nucl Med. 2008 Dec;33(12):906-8.
103. Sung M.S., Lee G.K., Kang H.S., Kwon S.T., Park J.G., Suh J.S., Cho G.H., Lee S.M., Chung M.H., Resnick D. Sacrococcygeal chordoma: MR imaging in 30 patients. Skeletal Radiol. 2005 Feb;34(2):87-94.
104. Vujovic., Henderson S., Presneau., Odell E,m Jacques., Tirabosco., Boshoff C., Flanagan. Brachyury, a crucial regulator of notochordal development, is a novel biomarker for chordomas A.M. J Pathol. 2006 Jun;209(2):157-65.
105. Rosenberg A.E., Brown G.A., Bhan A.K., Lee J.M. Chondroid chordoma-a variant of chordoma. A morphologic and immunohistochemical study. Am J Clin Pathol. 1994 Jan;101(1):36-41.
106. Hanna S.A., Tirabosco., Amin A., Polock R.C., Skinner J.A., Cannon S.R., Saifuddin A., Briggs T.W.R. Dedifferentiated chordoma: a report of four cases arising 'de novo'.J Bone Joint Surg Br. 2008 May;90(5):652-6.
107. Bisceglia M., D/Angelo V.A., Guglielmi G., Dor D.B., Pasquinelli G. Dedifferentiated chordoma of the thoracic spine with rhabdomyosarcomatous differentiation. Report of a case and review of the literature.Ann Diagn Pathol. 2007 Aug;11(4):262-73.
108. Cha Y.J., Hong C-K.,Kim D-S., Lee S-K., Park H.J., Kim S.H. Poorly differentiated chordoma with loss of SMARCB1/INI1 expression in pediatric patients: A report of two cases and review of the literature. Neuropathology. 2018 Feb;38(1):47-53.
109. Shih A.R., Cote G.M., Chebib I., Choy E., DeLaney T., Deshpande V., Hoenicek F., Miao R., Schwab J.H., Nielsen G.P., Chen Y-L. Clinicopathologic characteristics of poorly differentiated chordoma.Mod Pathol. 2018 Aug;31(8):1237-1245.
110. Hoch B.L., Nielsen G.P., Liebsch N.J., Rosenberg A.E. Base of skull chordomas in children and adolescents: a clinicopathologic study of 73 cases.Am J Surg Pathol. 2006 Jul;30(7):811-8.
111. Kallen M.E. The 2020 WHO Classification / M.E. Kallen, J.L. Hornick // American Journal of Surgical Pathology. 2021. № 45(1). P. 1–23.
112. Werner M. Giant cell tumour of bone: morphological, biological and histogenetical aspects. Int Orthop. 2006 Dec;30(6):484-9.
113. Gomes C.C., Diniz M.G., Amaral F.R., Antonini Guimarães B.V., Gomez R.S. The highly prevalent H3F3A mutation in giant cell tumors of bone is not shared by sporadic central giant cell lesion of the jaws. Oral Surg Oral Med Oral Pathol Oral Radiol. 2014 Nov;118(5):583-5.
114. Presneau N., Baumhoer D., Behjati S., Pillay N., Tarpey P., Campbell PJ., Jundt G., Hamoudi R., Wedge D.C., Loo P.V., Hassan A.B., Khatri B., Ye H., Tirabosco R., Amary M.F., Flanagan A.M. Diagnostic value of H3F3A mutations in giant cell tumor of bone compared to osteoclast-rich mimics. J Pathol Clin Res. 2015 Mar 16;1(2):113-23.
115. Lüke J., von Baer A., Schreiber J., Lübbehüsen C., Breining T., Mellert K., Marienfeld R., Schultheiss M., Möller P., Barth TFE. H3F3A mutation in giant cell tumor of the bone is detected by immunohistochemistry using a monoclonal antibody against the G34W mutated site of the histone H3.3 variant. Histopathology. 2017 Jul;71(1):125-133.
116. Amary F., Berisha F., Ye H, Gupta M., Gutteridge A., Baumhoer D., Gibbons R., Tirabosco R., O'Donnell P., Flanagan A.M. H3F3A (Histone 3.3) G34W Immunohistochemistry: A Reliable Marker Defining Benign and Malignant Giant Cell Tumor of Bone. Am J Surg Pathol. 2017 Aug;41(8):1059-1068.
117. Behjati S., Tarpey P.S., Presneau N., Scheipl S., Pillay N., Van Loo P., Wedge D.C., Cooke S.L., Gundem G., Davies H., Nik-Zainal S., Martin S., McLaren S., Goodie V., Robinson B., Butler A., Teague J.W., Halai D., Khatri B., Myklebost O., Baumhoer D., Jundt G., Hamoudi R., Tirabosco R., Amary M.F., Futreal P.A., Stratton M.R, Campbell PJ, Flanagan AM. Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone. Nat Genet. 2013 Dec;45(12):1479-82.
118. Aoki J., Watanabe H., Shinozaki T., Takagishi K., Ishijima H., Oya N., Sato N., Inoue T., Endo K. FDG PET of primary benign and malignant bone tumors: standardized uptake value in 52 lesions. Radiology. 2001 Jun;219(3):774-7.
119. McKinney AM, Reichert P, Short J, Dhurairaj T, SantaCruz K, McKinney Z, Kieffer S. Metachronous, multicentric giant cell tumor of the sphenoid bone with histologic, CT, MR imaging, and positron-emission tomography/CT correlation. AJNR Am J Neuroradiol. 2006 Nov-Dec;27(10):2199-201.
120. Luengo-Alonso G. Denosumab treatment for giant-cell tumor of bone: a systematic review of the literature / G. Luengo-Alonso [et al.] // Archives of Orthopaedic and Trauma Surgery. 2019. № 139(10). P. 1339–1349.
121. Rosario, M. Surveillance for lung metastasis from giant cell tumor of bone / M. Rosario, H.S. Kim, J.Y. Yun, I. Han // Journal of Surgical Oncology – 2017. – № 116(7). – P.907–913.
122. Dubory, A. Interest of Denosumab for the treatment of giant-cells tumors and Aneurysmal bone cysts of the spine. About nine cases / A. Dubory, G. Missenard, J. Domont, C. Court // Trauma, J Orthop. 2016. № 30(8). P. 5–6.
123. Wojcik, J. Denosumab-treated giant cell tumor of bone exhibits morphologic overlap with malignant giant cell tumor of bone / J. Wojcik [et al.] // American Journal of Surgical Pathology. 2016. № 40(1). P. 72–80.
124. Charles, J.F. Osteoclasts: More than “bone eaters” / J.F. Charles, A.O. Aliprantis // Trends in Molecular Medicine. 2014. № 20(8). P.449–459.
125. Nishida J., Sim F.H., Wenger D.E., Unni K.K. Malignant fibrous histiocytoma of bone. A clinicopathologic study of 81 patients. Cancer. 1997 Feb 1;79(3):482-93.
126. Huvos A.G., Heilweil M., Bretsky S.S. The pathology of malignant fibrous histiocytoma of bone. A study of 130 patients. Am J Surg Pathol. 1985 Dec;9(12):853-71.
127. Domson G.F., Shahlaee A., Reith J.D., Bush C.H., Gibbs C.P. Infarct-associated bone sarcomas. Clin Orthop Relat Res. 2009 Jul;467(7):1820-5.
128. Douya H., Yakayama R., Beppu Y., Hasegawa T. Malignant fibrous histiocytoma associated with diaphyseal medullary stenosis Clin Orthop Relat Res. 2002 Jul:(400):211-16.
129. Ali N.M., Niada S., Brini A.T., Moris M.R., Kurusamy S., Alholle A., Huen D., Antonescu C.R., Tirode F., Sumathi V., Latif F.J Genomic and transcriptomic characterisation of undifferentiated pleomorphic sarcoma of bone Pathol. 2019 Feb;247(2):166-176.
130. Romeo S., Bovee J.V.M.G., Kroon H.M., Tirabosco R., Natali C., Zanatta L., Sciot R., Mertens F., Athanasou N., Alberghini M., Szuhai K., Hogendoorn P.C.W., Dei Tos A.P. Malignant fibrous histiocytoma and fibrosarcoma of bone: a re-assessment in the light of currently employed morphological, immunohistochemical and molecular approaches. Virchows Arch. 2012 Nov;461(5):561-70.
131. Bacci G., Picci P., Mercuri M., Broni F., Ferrari S. Neoadjuvant chemotherapy for high grade malignant fibrous histiocytoma of bone Clin Orthop Relat Res. 1998 Jan:(346):178-89.
132. Douya H., Yokoyama R., Beppu Y., Hasegawa T. Malignant fibrous histiocytoma associated with diaphyseal medullary stenosis Clin Orthop Relat Res. 2002 Jul:(400):211-6.
133. Yokoyama R., Tsuneyoshi M., Enjoji M., Shinohara N., Masuda S. Prognostic factors of malignant fibrous histiocytoma of bone. A clinical and histopathologic analysis of 34 cases Cancer. 1993 Sep 15;72(6):1902-8.